Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 180,537,536
  • Shares Outstanding, K 2,757,140
  • Annual Sales, $ 39,807 M
  • Annual Income, $ 5,691 M
  • 36-Month Beta 0.79
  • Price/Sales 4.53
  • Price/Book 4.11

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.54 +8.16%
on 01/26/17
65.87 -0.59%
on 02/15/17
+2.95 (+4.72%)
since 01/20/17
3-Month
58.56 +11.82%
on 12/30/16
65.87 -0.59%
on 02/15/17
+3.18 (+5.10%)
since 11/21/16
52-Week
49.63 +31.94%
on 02/24/16
65.87 -0.59%
on 02/15/17
+15.36 (+30.65%)
since 02/19/16

Most Recent Stories

More News
Can Carl Icahn Save Bristol Myers Squibb?

Bristol-Myers Squibb Company (BMY) experienced slight growth after Carl Icahn, billionaire activist-investor, reportedly wants to take stake in the company.

MRK : 65.48 (+0.14%)
BMY : 54.78 (+0.35%)
STEER & Merck in Partnership for Collaborative Research on Processing Special Effect Pigments

Scientists From Two Companies to Accelerate Development of Appropriate Technology for Adoption by Plastic Industry

MRK : 65.48 (+0.14%)
The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson

The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson

AZN : 29.01 (-0.51%)
MRK : 65.48 (+0.14%)
JNJ : 119.66 (+0.67%)
AGN : 247.16 (-0.08%)
VRX : 16.40 (+2.24%)
STEER & Merck in Partnership for Collaborative Research on Processing Special Effect Pigments

BANGALORE, February 21, 2017 /PRNewswire/ --

MRK : 65.48 (+0.14%)
The Zacks Analyst Blog Highlights: Merck, PNC Financial, Express Scripts, VeriSign and Martin Marietta

The Zacks Analyst Blog Highlights: Merck, PNC Financial, Express Scripts, VeriSign and Martin Marietta

PNC : 127.55 (+0.54%)
ESRX : 71.37 (+2.00%)
MRK : 65.48 (+0.14%)
VRSN : 82.98 (+0.83%)
MLM : 219.98 (+1.12%)
Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ

The main news this week was an update from Merck (MRK) regarding its Alzheimer's disease drug.

AZN : 29.01 (-0.51%)
JNJ : 119.66 (+0.67%)
MRK : 65.48 (+0.14%)
LLY : 80.36 (-0.04%)
AGN : 247.16 (-0.08%)
VRX : 16.40 (+2.24%)
BMY : 54.78 (+0.35%)
Q4 Earnings Season Scorecard & Top Analyst Reports

Q4 Earnings Season Scorecard & Top Analyst Reports

PNC : 127.55 (+0.54%)
ESRX : 71.37 (+2.00%)
MRK : 65.48 (+0.14%)
TOT : 51.91 (+2.69%)
VRSN : 82.98 (+0.83%)
MLM : 219.98 (+1.12%)
What's Driving Lilly's (LLY) Shares after 2016 Decline?

After a rather difficult 2016, share price of pharma giant, Eli Lilly & Company (LLY) has picked up in 2017.

MRK : 65.48 (+0.14%)
LLY : 80.36 (-0.04%)
INCY : 122.36 (+1.55%)
TEVA : 36.65 (+4.12%)
Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback

Merck's (MRK) news represents the latest setback in the pharma and biotech sector's quest to find a treatment for Alzheimer's.

AZN : 29.01 (-0.51%)
JNJ : 119.66 (+0.67%)
MRK : 65.48 (+0.14%)
LLY : 80.36 (-0.04%)
NVS : 77.04 (-0.21%)
AMGN : 173.14 (-0.09%)
BIIB : 286.90 (-0.71%)
Merck's Fight Against Infectious Disease Goes Digital with Launch of ILUM Health Solutions

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of ILUM Health Solutions, which provides enterprise-wide disease management tools and services...

MRK : 65.48 (+0.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines...

See More

Support & Resistance

2nd Resistance Point 66.27
1st Resistance Point 65.87
Last Price 65.48
1st Support Level 64.99
2nd Support Level 64.51

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.